SeaStar Medical reports 69% survival in pediatric AKI registry for QUELIMMUNE therapy

Reuters03-30

SeaStar Medical reports 69% survival in pediatric AKI registry for QUELIMMUNE therapy

SeaStar Medical highlighted new real-world registry data plus mechanistic research on its Selective Cytopheretic Device therapy at AKI & CRRT 2026, with posters already available starting March 29.
18-month post-approval SAVE Registry analysis in pediatric AKI patients on CRRT reported no device-related adverse events.
Preliminary outcomes from registry cohort showed 69% survival at Day 28 plus Day 60, consistent with prior SCD-PED trial experience.
Separate in vitro gene expression analysis indicated SCD shifted pro-inflammatory monocytes toward an anti-inflammatory, reparative phenotype.
Company also hosted an educational symposium on pediatric AKI on March 30 to support broader clinical adoption of QUELIMMUNE in pediatric AKI with sepsis requiring renal replacement therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603300820PRIMZONEFULLFEED9680450) on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623317240?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623317240","market":"us","top_or_hot":-1,"title":"SeaStar Medical reports 69% survival in pediatric AKI registry for QUELIMMUNE therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SeaStar Medical reports 69% survival in pediatric AKI registry for QUELIMMUNE therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          SeaStar Medical highlighted new real-world registry data plus mechanistic research on its Selective Cytopheretic Device therapy at AKI &amp; CRRT 2026, with posters already available starting March 29.\n        </li>\n<li>\n          18-month post-approval SAVE Registry analysis in pediatric AKI patients on CRRT reported no device-related adverse events.\n        </li>\n<li>\n          Preliminary outcomes from registry cohort showed 69% survival at Day 28 plus Day 60, consistent with prior SCD-PED trial experience.\n        </li>\n<li>\n          Separate in vitro gene expression analysis indicated SCD shifted pro-inflammatory monocytes toward an anti-inflammatory, reparative phenotype.\n        </li>\n<li>\n          Company also hosted an educational symposium on pediatric AKI on March 30 to support broader clinical adoption of QUELIMMUNE in pediatric AKI with sepsis requiring renal replacement therapy.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603300820PRIMZONEFULLFEED9680450) on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SeaStar Medical reports 69% survival in pediatric AKI registry for QUELIMMUNE therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeaStar Medical reports 69% survival in pediatric AKI registry for QUELIMMUNE therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 20:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SeaStar Medical reports 69% survival in pediatric AKI registry for QUELIMMUNE therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          SeaStar Medical highlighted new real-world registry data plus mechanistic research on its Selective Cytopheretic Device therapy at AKI &amp; CRRT 2026, with posters already available starting March 29.\n        </li>\n<li>\n          18-month post-approval SAVE Registry analysis in pediatric AKI patients on CRRT reported no device-related adverse events.\n        </li>\n<li>\n          Preliminary outcomes from registry cohort showed 69% survival at Day 28 plus Day 60, consistent with prior SCD-PED trial experience.\n        </li>\n<li>\n          Separate in vitro gene expression analysis indicated SCD shifted pro-inflammatory monocytes toward an anti-inflammatory, reparative phenotype.\n        </li>\n<li>\n          Company also hosted an educational symposium on pediatric AKI on March 30 to support broader clinical adoption of QUELIMMUNE in pediatric AKI with sepsis requiring renal replacement therapy.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603300820PRIMZONEFULLFEED9680450) on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BN0W2T93.GBP","symbol_name":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL5rPsql:1","article_id":"2623317240","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623317240","pubTimestamp":1774873226,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SeaStar Medical highlighted new real-world registry data plus mechanistic research on its Selective Cytopheretic Device therapy at AKI & CRRT 2026, with posters already available starting March 29.18-month post-approval SAVE Registry analysis in pediatric AKI patients on CRRT reported no device-related adverse events.Preliminary outcomes from registry cohort showed 69% survival at Day 28 plus Day 60, consistent with prior SCD-PED trial experience.Separate in vitro gene expression analysis indicated SCD shifted pro-inflammatory monocytes toward an anti-inflammatory, reparative phenotype.Company also hosted an educational symposium on pediatric AKI on March 30 to support broader clinical adoption of QUELIMMUNE in pediatric AKI with sepsis requiring renal replacement therapy.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4082":"医疗保健设备","ICU":"SeaStar Medical Holding Corporation","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"SeaStar Medical报告称，QUELIMMUNE疗法在儿科AKI登记处的存活率为69%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICU":0.9,"NDAQ":0.9},"content_text":"SeaStar Medical reports 69% survival in pediatric AKI registry for QUELIMMUNE therapy\n    \n\n\n          SeaStar Medical highlighted new real-world registry data plus mechanistic research on its Selective Cytopheretic Device therapy at AKI & CRRT 2026, with posters already available starting March 29.\n        \n\n          18-month post-approval SAVE Registry analysis in pediatric AKI patients on CRRT reported no device-related adverse events.\n        \n\n          Preliminary outcomes from registry cohort showed 69% survival at Day 28 plus Day 60, consistent with prior SCD-PED trial experience.\n        \n\n          Separate in vitro gene expression analysis indicated SCD shifted pro-inflammatory monocytes toward an anti-inflammatory, reparative phenotype.\n        \n\n          Company also hosted an educational symposium on pediatric AKI on March 30 to support broader clinical adoption of QUELIMMUNE in pediatric AKI with sepsis requiring renal replacement therapy.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603300820PRIMZONEFULLFEED9680450) on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623317240","isCrawlerRequest":true}